###### 

Patient characteristics

  Baseline characteristics Parameters                                                            Cohort 1 (N=235) N, (%)   Cohort 2 (N=407) N, (%)
  ---------------------------------------------------------------------------------------------- ------------------------- -------------------------
  Age, yrs, mean±SD                                                                              49.3±7.1                  46.6±9.4
  Female, n (%)                                                                                  45 (19.1)                 107 (26.3)
  VL (HIV-RNA) \<50 copies/mL, n (%)[a](#TF0001_19786){ref-type="table-fn"} at study enrolment   192 (85)                  298 (74.9)
  CD4+\<100 cells/µL, n (%)[b](#TF0002_19786){ref-type="table-fn"} at study enrolment            7 (3.1)                   25 (6.2)
  Duration of HIV infection, n (%)                                                                                         
  0--1 year                                                                                      0                         53 (13.0)
  \>1--10 years                                                                                  6 (2.6)                   82 (20.1)
  \>10--15 years                                                                                 62 (26.4)                 66 (16.2)
  \>15--20 years                                                                                 89 (37.9)                 85 (20.9)
  \>20 years                                                                                     76 (32.3)                 110 (27.0)
  NA                                                                                             2 (0.9)                   11 (2.7)
  CDC clinical stage, n (%)                                                                                                
  A                                                                                              30 (12.8)                 139 (34.2)
  B                                                                                              80 (34.0)                 121 (29.7)
  C                                                                                              125 (53.2)                147 (36.1)
  Time since first DRV dose (days), at study enrolment -- mean±SD                                1242±208                  501±402
  Study Duration, days -- mean±SD                                                                812±286                   583±188
  DRV dose at study entry, mg/day, n (%)                                                                                   
  1200                                                                                           232                       262
  800                                                                                            3                         145

VL data only available in 226 Cohort 1 and 398 Cohort 2 patients.

CD4+ data only available in 226 Cohort 1 and 403 Cohort 2 patients.

###### 

Patient characteristics

  Virological EfficacyParameters                                                    Cohort 1 (N=235) N, (%)   Cohort 2 (N=407) N, (%)
  --------------------------------------------------------------------------------- ------------------------- -------------------------
  LSV VL \[HIV-RNA \<50 copies/mL\], n (%)[a](#TF0003_19786){ref-type="table-fn"}                             
  All                                                                               203 (88.6)                331 (83.6)
  BL VL \<50 copies/mL                                                              177 (94.1)                263 (89.2)
  BL VL ≥50 copies/mL                                                               19 (59.4)                 60 (65.2)
  No values for BL VL                                                               7 (77.8)                  8 (88.9)
  Total discontinuations at LSV, n (%)                                              56 (24.7)                 71 (17.4)
  Reasons for discontinuation, n (%)                                                                          
  Insufficient virological response                                                 8 (3.4)                   4 (1.0)
  Death                                                                             10 (4.3)                  9 (2.2)
  Study emergent adverse event                                                      3 (1.3)                   9 (2.2)
  Other study emergent medical reason                                               0                         1 (0.2)
  Lack of compliance                                                                4 (1.7)                   8 (2.0)
  Lost to follow-up                                                                 23 (9.8)                  18 (4.4)
  Other                                                                             9 (3.8)                   20 (4.9)

VL data only available in 226 Cohort 1 and 398 Cohort 2 patients.
